The human nervous system plays a pivotal role in controlling most functions of the body and mind. Generally, the nervous systems that send signals to tissues and organs to suppress damage or injury, occasionally fails to work effectively, which results in diseases like rheumatoid arthritis and inflammatory bowel disease. Traditionally, physicians used expensive drugs specifically designed to suppress inflammation or other injuries. Most often than not, these traditional pills doesn’t work for all the patients. The drugs travel through the bloodstream and interact with other organs and the patient has to deal with the side effects. Besides, the impact of the drug on the targeted area is also not effective. In such scenarios, using electrical therapy or bioelectronic medicine acts as a boon for physicians to treat fatal human diseases. Now, imagine a world where diseases like cancer, diabetes, and arthritis are treated with electricity rather than unpleasant, bitter pills or chemotherapy.
Making this electrical therapy a reality is NeuSpera Medical. A start-up company, NeuSpera Medical is at the forefront of offering bioelectric medicines to treat many chronic and debilitating diseases. NeuSpera Medical’s expert team has engineered patented midfield powering technology to develop ultra miniaturized systems that are safer, smaller, and more affordable. It also drives greater accessibility and adoption while allowing users to take control of their treatment. NeuSpera’s platform uses evanescent and propagating electromagnetic waves to power implanted medical devices located 10 cm deep in tissue from a distance. The physician can use the patient’s body as a natural waveguide to ensure more power is delivered to the targeted area. NeuSpera’s medical device can be inserted into target anatomies that were previously inaccessible. When used to power electrical stimulators, these devices have successfully paced a heart and treated neurological diseases.
Our ultimate aim is to bring this technology forward in order to improve the care and outcomes of patients struggling with fatal and devastating diseases
“Neuspera powered implants may lead to earlier adoption of neuromodulation based treatment therapies due to its much smaller form factor and ease of use for both patients and clinicians,” says Milton M. Morris, president and CEO of Neuspera.
Neuspera’s technology delivers milliwatts of power into ultra-miniaturized devices. While a large amount of power is applied to superficial targets, Neuspera’s technology excels in transmitting through bone, fat, and muscle to deep tissue targets. A single compact transmitter can generate power to multiple implants. The power harvesting unit can be attached to a variety of interfaces to sense or treat deep brain regions, peripheral nerves, cardiac muscle or ganglia. Morris notes that because the Neuspera platform is powered externally, it offers an opportunity for patient engagement. “Patients will have a fair amount of control over the delivery of their therapy, more so than in the past, which gives us an opportunity to engage with patients and providers in ways that haven’t been done in the past.”
Neuspera’s hermetically sealed implantable module is much smaller than other neuromodulation devices and reduces implant procedure complexity, patient complication, and post-surgical pain. “The Neuspera platform is applicable to a wide range of medical indications that are currently using the traditional and much larger implantable pulse generator and lead approach,” says Morris. There is no doubt that Neuspera’s less invasive technology advancement will act as a catalyst for the growth of neuromodulation in the treatment of many chronic disease states. “Our ultimate aim is to bring this technology forward in order to improve the care and outcomes of patients struggling with fatal and devastating diseases,” concludes Morris.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: